ALAUNOS THERAPEUTICS INC
TCRT
Health Care
2
exclusion reasons
2 themes
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Alaunos Therapeutics, a clinical-stage biotech formerly known as Ziopharm Oncology, settled with The University of Texas MD Anderson Cancer Center in December 2025 for $285,055 over unpaid invoices under a 2019 Research and Development Agreement. The settlement is payable in installments through May 2026. While this is a contractual dispute rather than a regulatory enforcement action, it reflects a pattern of financial mismanagement at a company that repeatedly pivoted strategy while failing to honor obligations. Alaunos discontinued its Repibresib program after Phase 2b failure, then shifted to a merger strategy, raising concerns about its ability to sustain operations and meet commitments to research partners.
Alaunos Therapeutics is a clinical-stage oncology company developing TCR-T cell therapies. Its preclinical drug development pipeline requires animal testing for regulatory compliance and safety assessment.
Research Sources
2 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.